{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:28:29Z","timestamp":1786994909704,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.neurol.2018.01.378","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T09:41:39Z","timestamp":1538646099000},"page":"675-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"174","author":[{"given":"A.","family":"Ungureanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-2289","authenticated-orcid":false,"given":"G.","family":"Ahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sellal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurol.2018.01.378_bib0255","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2018.01.378_bib0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-5728(87)90031-2","article-title":"Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin\/oligodendrocyte glycoprotein (MOG)","volume":"17","author":"Linington","year":"1987","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.neurol.2018.01.378_bib0265","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3940(01)01949-8","article-title":"Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica","volume":"307","author":"Haase","year":"2001","journal-title":"Neurosci Lett"},{"issue":"6","key":"10.1016\/j.neurol.2018.01.378_bib0270","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijdevneu.2012.05.004","article-title":"The Brown Norway opticospinal model of demyelination: does it mimic multiple sclerosis or neuromyelitis optica?","volume":"30","author":"Collongues","year":"2012","journal-title":"Int J Dev Neurosci"},{"issue":"2","key":"10.1016\/j.neurol.2018.01.378_bib0275","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2353\/ajpath.2007.061098","article-title":"Anti-viral T-cell immunity+anti-CNS autoantibody=a model for human acute disseminated encephalomyelitis or multiple sclerosis relapse?","volume":"170","author":"Sobel","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.neurol.2018.01.378_bib0280","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.neurol.2018.01.378_bib0285","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/ene.12759","article-title":"Antibody biomarkers in CNS demyelinating diseases - a long and winding road","volume":"22","author":"Berger","year":"2015","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2018.01.378_bib0290","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2018.01.378_bib0295","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"9451","key":"10.1016\/j.neurol.2018.01.378_bib0300","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"Pt 5","key":"10.1016\/j.neurol.2018.01.378_bib0305","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/j.neurol.2018.01.378_bib0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jns.2015.05.034","article-title":"Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: a review","volume":"355","author":"Pereira","year":"2015","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"10.1016\/j.neurol.2018.01.378_bib0315","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2011.02.018","article-title":"Neuromyelitis optica and astrocytic damage in its pathogenesis","volume":"306","author":"Fujihara","year":"2011","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.neurol.2018.01.378_bib0320","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2018.01.378_bib0325","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp.2009.196550","article-title":"Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases","volume":"82","author":"Petzold","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2018.01.378_bib0330","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","article-title":"Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker","volume":"80","author":"Misu","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.neurol.2018.01.378_bib0335","doi-asserted-by":"crossref","first-page":"e23489","DOI":"10.1371\/journal.pone.0023489","article-title":"The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis","volume":"6","author":"Storoni","year":"2011","journal-title":"Plos One"},{"issue":"12","key":"10.1016\/j.neurol.2018.01.378_bib0340","doi-asserted-by":"crossref","DOI":"10.1111\/ene.12679","article-title":"Neuromyelitis optica: a positive appraisal of seronegative cases","volume":"22","author":"Bernard-Valnet","year":"2015","journal-title":"Eur J Neurol"},{"issue":"24","key":"10.1016\/j.neurol.2018.01.378_bib0345","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.378_bib0350","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.neurol.2018.01.378_bib0355","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00415-010-5780-4","article-title":"Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients","volume":"258","author":"Akman-Demir","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2018.01.378_bib0360","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.neurol.2018.01.378_bib0365","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clineuro.2011.10.048","article-title":"Antibodies to CV2\/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature","volume":"114","author":"Jarius","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"issue":"18","key":"10.1016\/j.neurol.2018.01.378_bib0370","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e3181dc1a7f","article-title":"NMDA receptor encephalitis mimicking seronegative neuromyelitis optica","volume":"74","author":"Kruer","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurol.2018.01.378_bib0375","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-2007-1004521","article-title":"Detection of autoantibodies against NMDA-type glutamate receptor in a patient with recurrent optic neuritis and transient cerebral lesions","volume":"38","author":"Ishikawa","year":"2007","journal-title":"Neuropediatrics"},{"issue":"3","key":"10.1016\/j.neurol.2018.01.378_bib0380","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2018.01.378_bib0385","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurol.2018.01.378_bib0390","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/jnnp.2005.077784","article-title":"Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event","volume":"77","author":"Rauer","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2018.01.378_bib0395","doi-asserted-by":"crossref","first-page":"673503","DOI":"10.1155\/2015\/673503","article-title":"Decreased frequency of circulating myelin oligodendrocyte glycoprotein B lymphocytes in patients with relapsing-remitting multiple sclerosis","volume":"2015","author":"Elong Ngono","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.neurol.2018.01.378_bib0400","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2051-5960-2-35","article-title":"Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain","volume":"2","author":"Saadoun","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"10.1016\/j.neurol.2018.01.378_bib0405","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-013-1116-7","article-title":"Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica","volume":"125","author":"Misu","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.neurol.2018.01.378_bib0410","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurol.2018.01.378_bib0415","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci US"},{"issue":"11","key":"10.1016\/j.neurol.2018.01.378_bib0420","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.4049\/jimmunol.0901906","article-title":"Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes","volume":"183","author":"Jager","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.neurol.2018.01.378_bib0425","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1749-6632.2009.05133.x","article-title":"Th1 and Th17 cells: adversaries and collaborators","volume":"1183","author":"Damsker","year":"2010","journal-title":"Ann NY Acad Sci"},{"issue":"32","key":"10.1016\/j.neurol.2018.01.378_bib0430","doi-asserted-by":"crossref","first-page":"14292","DOI":"10.1073\/pnas.1009234107","article-title":"Proinflammatory T helper type 17 cells are effective B-cell helpers","volume":"107","author":"Mitsdoerffer","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.neurol.2018.01.378_bib0435","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1002\/eji.200839179","article-title":"Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE","volume":"39","author":"Isaksson","year":"2009","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.neurol.2018.01.378_bib0440","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1177\/1352458508088943","article-title":"Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment","volume":"14","author":"Moreh","year":"2008","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.neurol.2018.01.378_bib0445","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Probstel","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2018.01.378_bib0450","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"Hoftberger","year":"2015","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.neurol.2018.01.378_bib0455","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.neurol.2018.01.378_bib0460","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2018.01.378_bib0465","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/1352458512470310","article-title":"Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica","volume":"19","author":"Rostasy","year":"2013","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.neurol.2018.01.378_bib0470","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","article-title":"MOG antibody-related disorders: common features and uncommon presentations","volume":"264","author":"Cobo-Calvo","year":"2017","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2018.01.378_bib0475","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/ene.12058","article-title":"Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients","volume":"20","author":"Kiyat-Atamer","year":"2013","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2018.01.378_bib0480","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.neurol.2018.01.378_bib0485","doi-asserted-by":"crossref","first-page":"e007766","DOI":"10.1136\/bmjopen-2015-007766","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis","volume":"5","author":"Nakajima","year":"2015","journal-title":"BMJ open"},{"issue":"2","key":"10.1016\/j.neurol.2018.01.378_bib0490","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WNO.0b013e31823c9b6c","article-title":"Relationship between NMO-antibody and anti-MOG antibody in optic neuritis","volume":"32","author":"Kezuka","year":"2012","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.neurol.2018.01.378_bib0495","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2018.01.378_bib0500","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Probstel","year":"2015","journal-title":"J Neuroinflammation"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378717307415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378717307415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:37:56Z","timestamp":1758519476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378717307415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0035378717307415"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2018.01.378","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2018.01.378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}